Invitris, an IZB-based biotech startup, has announced that it has been selected for the European Innovation Council (EIC) Accelerator. This selection places Invitris among the 71 pioneering companies chosen from a highly competitive pool of over 1,200 applicants in the program’s most rigorous funding round to date.

The EIC Accelerator is Europe’s largest and most prestigious funding initiative for high-risk, high-impact startups in deep tech and life sciences. Through a combination of non-dilutive grants and equity investment, it provides selected companies with the resources needed to scale their innovations and bring breakthrough technologies to market.

What This Means for Invitris
This multi-million-euro funding will enable Invitris to:

• Scale its Phactory platform to develop next-generation, personalized protein-based therapies
• Accelerate clinical translation and regulatory approvals for its innovative treatments
• Advance the fight against antimicrobial resistance (AMR), a growing global health crisis

According to Dr. Patrick Grossmann, CEO & co-founder of Invitris, “These funds will allow us to bring our technology to the next level, making personalized treatments a reality. The EIC Accelerator support validates our mission and will help us move toward clinical applications faster.”

About the EIC Accelerator and Its Impact
The EIC Accelerator is a flagship program under Horizon Europe, designed to support groundbreaking startups with the potential to become global leaders in their respective fields. In this round, the European Innovation Council awarded up to €161 million in grants and €226 million in equity investments to selected companies, with the goal of bridging the gap between research and commercialization.

This funding will allow Invitris to build upon its success as an IZB-based startup, further strengthening its position in the biotech and life sciences ecosystem. The company’s Phactory platform has the potential to revolutionize personalized medicine, offering scalable solutions for tailored protein-based therapies that address critical medical needs.

About Invitris GmbH
The universal platform technology from Invitris enables the generation of synthetic phages with highest yield and purity. Using this platform, the start-up develops phage-based drugs with completely novel mechanisms of action to cure drug-resistant infections.